{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:50Z","timestamp":1785842270135,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this meta-analysis was to assess the effectiveness and safety of secondary cytoreductive surgery plus chemotherapy (SCS\u2009+\u2009CT) in recurrent ovarian cancer (ROC). Our secondary purpose was to analyze whether patients could benefit from complete resection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched EMBASE, MEDLINE, the Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials, from inception to April 2021. We used appropriate scales to assess the risk of bias. Data from included studies that reported median PFS or OS were weighted by individual study sample size, and aggregated for meta-analysis. We calculated the pooled proportion of complications within 30\u00a0days after surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 13 articles, including three RCTs and ten retrospective cohort studies. A total of 4572 patients were included, of which 916 patients achieved complete resection, and all patients were comparable at baseline. Compared with chemotherapy alone, SCS\u2009+\u2009CT significantly improved the PFS (HR\u2009=\u20090.54, 95% CI: 0.43\u20130.67) and OS (HR\u2009=\u20090.60, 95% CI: 0.44\u20130.81). Contrary to the results of cohort studies, the meta-analysis of RCTs showed that SCS\u2009+\u2009CT could not bring OS benefits (HR\u2009=\u20090.93, 95% CI: 0.66\u20131.3). The subgroup analysis showed the prognostic importance of complete resection. Compared with chemotherapy alone, complete resection was associated with longer PFS (HR\u2009=\u20090.53, 95% CI: 0.45\u20130.61) and OS (HR\u2009=\u20090.56, 95% CI: 0.39\u20130.81), while incomplete resection had no survival benefit. Additionally, complete resection could maximize survival benefit compared with incomplete resection (HR\u2009=\u20090.56, 95% CI: 0.46\u20130.69; HR\u2009=\u20090.61, 95% CI: 0.50\u20130.75). The pooled proportion for complications at 30\u00a0days was 21% (95% CI: 0.12\u20130.30), and there was no statistical difference in chemotherapy toxicity between the two groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The review indicated that SCS\u2009+\u2009CT based regimens was correlated with better clinical prognosis for patients with recurrent ovarian cancer, but the interpretation of OS should be cautious. The meta-analysis emphasizes the importance of complete resection, suggesting that the potential benefits of prolonging survival may outweigh the disadvantages of any short-term complications associated with surgery.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13048-021-00842-9","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T15:03:24Z","timestamp":1626188604000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Ting","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6903-0625","authenticated-orcid":false,"given":"Mingrong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"842_CR1","doi-asserted-by":"publisher","unstructured":"Luvero D, Plotti F, Aloisia A, Montera R, Terranova C, Carlo De Cicco Nardone, Scaletta G, Lopez S, Miranda A, Capriglione S, Gatti A, Pierluigi Benedetti Panici, Angioli R. Ovarian cancer relapse: From the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28\u201338. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.05.014. Epub 2019 May 29. PMID: 31176270.","DOI":"10.1016\/j.critrevonc.2019.05.014"},{"issue":"8","key":"842_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.clon.2018.04.006","volume":"30","author":"M Bommert","year":"2018","unstructured":"Bommert M, Harter P, Heitz F, du Bois A. When should Surgery be used for Recurrent Ovarian Carcinoma? Clin Oncol (R Coll Radiol). 2018;30(8):493\u20137. https:\/\/doi.org\/10.1016\/j.clon.2018.04.006 Epub 2018 May 7 PMID: 29743148.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"842_CR3","doi-asserted-by":"publisher","unstructured":"Al Rawahi T, Lopes AD, Bristow RE, Bryant A, Elattar A, Chattopadhyay S, Galaal K. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. https:\/\/doi.org\/10.1002\/14651858.CD008765.pub3. PMID: 23450588; PMCID: PMC6457850.","DOI":"10.1002\/14651858.CD008765.pub3"},{"key":"842_CR4","doi-asserted-by":"publisher","unstructured":"Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schr\u00f6der W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702\u201310. https:\/\/doi.org\/10.1245\/s10434-006-9058-0. PMID: 17009163.","DOI":"10.1245\/s10434-006-9058-0"},{"key":"842_CR5","doi-asserted-by":"publisher","unstructured":"Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, P\u00f6lcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011;21(2):289\u201395. https:\/\/doi.org\/10.1097\/IGC.0b013e31820aaafd. PMID: 21270612.","DOI":"10.1097\/IGC.0b013e31820aaafd"},{"key":"842_CR6","doi-asserted-by":"publisher","unstructured":"Herzog TJ, Armstrong DK, Brady MF, Coleman RL, Einstein MH, Monk BJ, Mannel RS, Thigpen JT, Umpierre SA, Villella JA, Alvarez RD. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014;132(1):8\u201317. https:\/\/doi.org\/10.1016\/j.ygyno.2013.11.008. Epub 2013 Nov 15. PMID: 24239753; PMCID: PMC4702266.","DOI":"10.1016\/j.ygyno.2013.11.008"},{"issue":"1","key":"842_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1097\/IGC.0000000000000841","volume":"27","author":"R van de Laar","year":"2017","unstructured":"van de Laar R, Kruitwagen RF, Zusterzeel PL, Van Gorp T, Massuger LF. Correspondence: Premature Stop of the SOCceR Trial, a Multicenter Randomized Controlled Trial on Secondary Cytoreductive Surgery: Netherlands Trial Register Number: NTR3337. Int J Gynecol Cancer. 2017;27(1):2. https:\/\/doi.org\/10.1097\/IGC.0000000000000841 PMID: 28002207.","journal-title":"Int J Gynecol Cancer"},{"key":"842_CR8","doi-asserted-by":"publisher","unstructured":"Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779\u2013791. https:\/\/doi.org\/10.1016\/S1470-2045(17)30279-6. Epub 2017 Apr 21. PMID: 28438473; PMCID: PMC5715461.","DOI":"10.1016\/S1470-2045(17)30279-6"},{"issue":"20","key":"842_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019;381(20):1929\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1902626. PMID:31722153;PMCID:PMC6941470","journal-title":"N Engl J Med"},{"key":"842_CR10","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"AD Bois","year":"2017","unstructured":"Bois AD, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol. 2017;35:5501.","journal-title":"J Clin Oncol"},{"key":"842_CR11","doi-asserted-by":"crossref","unstructured":"A du Bois, J Sehouli, I Vergote, et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III\/ENGOT-ov20 Proc Am Soc Clin Oncol, 38 (suppl) (2020), Article 6000","DOI":"10.1200\/JCO.2020.38.15_suppl.6000"},{"issue":"4","key":"842_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","volume":"22","author":"T Shi","year":"2021","unstructured":"Shi T, Zhu J, Feng Y, Tu D, Zhang Y, Zhang P, Jia H, Huang X, Cai Y, Yin S, Jiang R, Tian W, Gao W, Liu J, Yang H, Cheng X, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):439\u201349. https:\/\/doi.org\/10.1016\/S1470-2045(21)00006-1 Epub 2021 Mar 8 PMID: 33705695.","journal-title":"Lancet Oncol"},{"key":"842_CR13","doi-asserted-by":"publisher","unstructured":"Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-09226-7. Epub ahead of print. PMID: 33067742.","DOI":"10.1245\/s10434-020-09226-7"},{"key":"842_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-0-387-48993-3_15","volume":"134","author":"PH Sugarbaker","year":"2007","unstructured":"Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res. 2007;134:247\u201364. https:\/\/doi.org\/10.1007\/978-0-387-48993-3_15 PMID: 17633058.","journal-title":"Cancer Treat Res"},{"issue":"7414","key":"842_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557 PMID:12958120;PMCID:PMC192859.","journal-title":"BMJ"},{"key":"842_CR16","doi-asserted-by":"publisher","unstructured":"Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88(1):144\u201353. https:\/\/doi.org\/10.1002\/(sici)1097-0142(20000101)88:1%3c144::aid-cncr20%3e3.3.co;2-o PMID: 10618617.","DOI":"10.1002\/(sici)1097-0142(20000101)88:1%3c144::aid-cncr20%3e3.3.co;2-o"},{"issue":"1","key":"842_CR17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/1096-9098(200009)75:1<24::aid-jso5>3.0.co;2-l","volume":"75","author":"RY Zang","year":"2000","unstructured":"Zang RY, Zhang ZY, Li ZT, Chen J, Tang MQ, Liu Q, Cai SM. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol. 2000;75(1):24\u201330. https:\/\/doi.org\/10.1002\/1096-9098(200009)75:1<24::aid-jso5>3.0.co;2-l PMID: 11025458.","journal-title":"J Surg Oncol"},{"issue":"3","key":"842_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1006\/gyno.2001.6404","volume":"83","author":"C Scarabelli","year":"2001","unstructured":"Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol. 2001;83(3):504\u201312. https:\/\/doi.org\/10.1006\/gyno.2001.6404 PMID: 11733963.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"842_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejso.2004.08.016","volume":"31","author":"B Gronlund","year":"2005","unstructured":"Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, H\u00f8gdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005;31(1):67\u201373. https:\/\/doi.org\/10.1016\/j.ejso.2004.08.016 PMID: 15642428.","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"842_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajog.2005.06.048","volume":"194","author":"A Ayhan","year":"2006","unstructured":"Ayhan A, Gultekin M, Taskiran C, Aksan G, Celik NY, Dursun P, Salman MC, Yuce K, Kucukali T. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol. 2006;194(1):49\u201356. https:\/\/doi.org\/10.1016\/j.ajog.2005.06.048 PMID: 16389009.","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"842_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.ejso.2009.03.010","volume":"35","author":"X Cheng","year":"2009","unstructured":"Cheng X, Jiang R, Li ZT, Tang J, Cai SM, Zhang ZY, Tian WJ, Zang RY. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC). Eur J Surg Oncol. 2009;35(10):1105\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2009.03.010 Epub 2009 May 13 PMID: 19443175.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"842_CR22","first-page":"506","volume":"54","author":"PN Rema","year":"2009","unstructured":"Rema PN, Suchetha S, Mathew AP, Mathew A, Sebastian P. Secondary cytoreduction in epithelial ovarian cancer recurrence: a perspective from a regional cancer center in India. J Reprod Med. 2009;54(8):506\u201310 PMID: 19769197.","journal-title":"J Reprod Med"},{"issue":"2","key":"842_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ijgo.2009.08.034","volume":"108","author":"JO Schorge","year":"2010","unstructured":"Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynaecol Obstet. 2010;108(2):123\u20137. https:\/\/doi.org\/10.1016\/j.ijgo.2009.08.034 Epub 2009 Nov 4 PMID: 19892337.","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"842_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/IGC.0b013e3182098002","volume":"21","author":"T Goto","year":"2011","unstructured":"Goto T, Takano M, Watanabe A, Miyamoto M, Kato M, Hirata J, Sasa H, Furuya K. Potential survival benefit of secondary cytoreductive surgery for recurrent epithelial ovarian, tubal, and peritoneal cancers. Int J Gynecol Cancer. 2011;21(2):263\u20138. https:\/\/doi.org\/10.1097\/IGC.0b013e3182098002 PMID: 21270609.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"842_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/jog.12222","volume":"40","author":"K Nasu","year":"2014","unstructured":"Nasu K, Kai K, Hirakawa T, Nishida M, Matsumoto H, Kawano Y, Narahara H. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors. J Obstet Gynaecol Res. 2014;40(3):791\u20136. https:\/\/doi.org\/10.1111\/jog.12222 Epub 2013 Nov 18 PMID: 24245582.","journal-title":"J Obstet Gynaecol Res"},{"key":"842_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijsu.2016.12.031","volume":"38","author":"XM Fan","year":"2017","unstructured":"Fan XM, Zhang J, Niu SH, Li KX, Song CZ. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases. Int J Surg. 2017;38:61\u20136. https:\/\/doi.org\/10.1016\/j.ijsu.2016.12.031 Epub 2016 Dec 24 PMID: 28027999.","journal-title":"Int J Surg"},{"issue":"9","key":"842_CR27","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/cncr.21845","volume":"106","author":"DS Chi","year":"2006","unstructured":"Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, Venkatraman ES, Aghajanian C, Sonoda Y, Abu-Rustum NR, Barakat RR. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106(9):1933\u20139. https:\/\/doi.org\/10.1002\/cncr.21845 PMID: 16572412.","journal-title":"Cancer"},{"issue":"4","key":"842_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/cncr.22447","volume":"109","author":"R Salani","year":"2007","unstructured":"Salani R, Santillan A, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Armstrong DK, Bristow RE. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109(4):685\u201391. https:\/\/doi.org\/10.1002\/cncr.22447 PMID: 17219441.","journal-title":"Cancer"},{"key":"842_CR29","doi-asserted-by":"publisher","unstructured":"Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1\u20131 cm after secondary cytoreduction. J Surg Oncol. 2010;101(3):244\u201350. https:\/\/doi.org\/10.1002\/jso.21491. PMID: 20112269.","DOI":"10.1002\/jso.21491"},{"issue":"6","key":"842_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/01443615.2019.1674264","volume":"40","author":"S Kumar","year":"2020","unstructured":"Kumar S, Srinivasan A, Phillips A, Madhupriya R, Pascoe J, Nevin J, Elattar A, Balega J, Cummins C, Sundar S, Kehoe ST, Singh K. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer? J Obstet Gynaecol. 2020;40(6):849\u201355. https:\/\/doi.org\/10.1080\/01443615.2019.1674264 Epub 2020 Jan 14 PMID: 31933417.","journal-title":"J Obstet Gynaecol"},{"issue":"2","key":"842_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/IGC.0000000000000598","volume":"26","author":"R van de Laar","year":"2016","unstructured":"van de Laar R, Kruitwagen RF, IntHout J, Zusterzeel PL, Van Gorp T, Massuger LF. Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands: A Population-Based Cohort Study. Int J Gynecol Cancer. 2016;26(2):268\u201375. https:\/\/doi.org\/10.1097\/IGC.0000000000000598 PMID: 26588237.","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"842_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/COC.0000000000000310","volume":"41","author":"NA Bickell","year":"2018","unstructured":"Bickell NA, Egorova N, Prasad-Hayes M, Franco R, Howell EA, Wisnivesky J, Deb P. Secondary Surgery Versus Chemotherapy for Recurrent Ovarian Cancer. Am J Clin Oncol. 2018;41(5):458\u201364. https:\/\/doi.org\/10.1097\/COC.0000000000000310 PMID:27391357;PMCID:PMC5665721.","journal-title":"Am J Clin Oncol"},{"key":"842_CR33","doi-asserted-by":"publisher","unstructured":"Chuang CM, Chou YJ, Yen MS, Chao KC, Twu NF, Wu HH, Wen KC, Chen YJ, Wang PH, Lai CR, Chou P. The role of secondary cytoreductive surgery in patients with recurrent epithelial ovarian, tubal, and peritoneal cancers: a comparative effectiveness analysis. Oncologist. 2012;17(6):847\u201355. https:\/\/doi.org\/10.1634\/theoncologist.2011-0373. Epub 2012 May 16. PMID: 22591974; PMCID: PMC3380884.","DOI":"10.1634\/theoncologist.2011-0373"},{"issue":"6","key":"842_CR34","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/j.1447-0756.2006.00460.x","volume":"32","author":"A Matsumoto","year":"2006","unstructured":"Matsumoto A, Higuchi T, Yura S, Mandai M, Kariya M, Takakura K, Fujii S. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynaecol Res. 2006;32(6):580\u20137. https:\/\/doi.org\/10.1111\/j.1447-0756.2006.00460.x PMID: 17100820.","journal-title":"J Obstet Gynaecol Res"},{"key":"842_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-2407-14-22","volume":"14","author":"R van de Laar","year":"2014","unstructured":"van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ, Gaarenstroom KN, Arts HJ, van Huisseling JC, Hermans RH, Pijnenborg JM, Schutter EM, Pelikan HM, Vollebergh JH, Engelen MJ, Inthout J, Kruitwagen RF, Massuger LF. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC Cancer. 2014;14:22. https:\/\/doi.org\/10.1186\/1471-2407-14-22 PMID:24422892;PMCID:PMC3897943.","journal-title":"BMC Cancer"},{"issue":"6","key":"842_CR36","doi-asserted-by":"publisher","first-page":"625.e1","DOI":"10.1016\/j.ajog.2019.06.009","volume":"221","author":"A Gockley","year":"2019","unstructured":"Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, Griggs JJ, Mantia-Smaldone G, Matulonis UA, Meyer LA, Niland J, O\u2019Malley DM, Wright AA. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019;221(6):625.e1-625.e14. https:\/\/doi.org\/10.1016\/j.ajog.2019.06.009 Epub 2019 Jun 14 PMID: 31207237.","journal-title":"Am J Obstet Gynecol"},{"key":"842_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejogrb.2018.06.036","volume":"228","author":"M Felsinger","year":"2018","unstructured":"Felsinger M, Minar L, Weinberger V, Rovny I, Zlamal F, Bienertova-Vasku J. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2018;228:154\u201360. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.06.036 Epub 2018 Jun 20 PMID: 29957400.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"842_CR38","doi-asserted-by":"publisher","unstructured":"Szczesny W, Langseth H, Myklebust T\u00c5, Kaern J, Trop\u00e9 C, Paulsen T. Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A\u00a0registry-based study. Acta Obstet Gynecol Scand. 2018;97(8):956\u2013965. https:\/\/doi.org\/10.1111\/aogs.13361. Epub 2018 May 22. PMID: 29790149.","DOI":"10.1111\/aogs.13361"},{"issue":"1","key":"842_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","volume":"136","author":"CK Lee","year":"2015","unstructured":"Lee CK, Lord S, Grunewald T, Gebski V, Hardy-Bessard AC, Sehouli J, Woie K, Heywood M, Schauer C, Vergote I, Scambia G, Ferrero A, Harter P, Pujade-Lauraine E, Friedlander M. Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial. Gynecol Oncol. 2015;136(1):18\u201324. https:\/\/doi.org\/10.1016\/j.ygyno.2014.09.017 Epub 2014 Oct 2 PMID: 25281492.","journal-title":"Gynecol Oncol"},{"key":"842_CR40","doi-asserted-by":"crossref","unstructured":"Silvia Ortega, Jos\u00e9 Angel M\u00ednguez, Jos\u00e9 Manuel Aramend\u00eda, Marta Santisteban, Fernando Martinez-Regueira, Pablo Mart\u00ed-Cruchaga, Juan Luis Alc\u00e1zar, Mat\u00edas Jurado. The impact of secondary cytoreductive surgery on survival in first recurrence of platinum sensitive epithelial ovarian cancer. Eur J Gynaecol Oncol. 2020, 41(4): 523\u2013530.","DOI":"10.31083\/j.ejgo.2020.04.8051"},{"issue":"6","key":"842_CR41","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e100","volume":"30","author":"M So","year":"2019","unstructured":"So M, Miyamoto T, Murakami R, Abiko K, Hamanishi J, Baba T, Mandai M. The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients. J Gynecol Oncol. 2019;30(6): e100. https:\/\/doi.org\/10.3802\/jgo.2019.30.e100 PMID:31576692;PMCID:PMC6779625.","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"842_CR42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2004.11.057","volume":"97","author":"M G\u00fcng\u00f6r","year":"2005","unstructured":"G\u00fcng\u00f6r M, Orta\u00e7 F, Arvas M, K\u00f6sebay D, S\u00f6nmezer M, K\u00f6se K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol. 2005;97(1):74\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2004.11.057 PMID: 15790440.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"842_CR43","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdn591","volume":"20","author":"H Oksefjell","year":"2009","unstructured":"Oksefjell H, Sandstad B, Trop\u00e9 C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol. 2009;20(2):286\u201393. https:\/\/doi.org\/10.1093\/annonc\/mdn591 Epub 2008 Aug 25 PMID: 18725390.","journal-title":"Ann Oncol"},{"issue":"37","key":"842_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008006","volume":"96","author":"A Takahashi","year":"2017","unstructured":"Takahashi A, Kato K, Matsuura M, Katsuda T, Matoda M, Nomura H, Okamoto S, Kanao H, Kondo E, Omatsu K, Utsugi K, Takeshima N. Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients. Medicine (Baltimore). 2017;96(37): e8006. https:\/\/doi.org\/10.1097\/MD.0000000000008006 PMID:28906381;PMCID:PMC5604650.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"842_CR45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1136\/ijgc-2018-000142","volume":"29","author":"H Kajiyama","year":"2019","unstructured":"Kajiyama H, Suzuki S, Yoshikawa N, Kawai M, Shibata K, Nagasaka T, Kikkawa F. Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary. Int J Gynecol Cancer. 2019;29(5):910\u20135. https:\/\/doi.org\/10.1136\/ijgc-2018-000142 Epub 2019 Mar 5 PMID: 30839284.","journal-title":"Int J Gynecol Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00842-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00842-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:46:08Z","timestamp":1672793168000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00842-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["842"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00842-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}